Krystal Historical Cash Flow
| KRYS Stock | USD 190.40 8.11 4.45% |
Analysis of Krystal Biotech cash flow over time is an excellent tool to project Krystal Biotech future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Net Borrowings of 2.3 M or Stock Based Compensation of 41.9 M as it is a great indicator of Krystal Biotech ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Krystal Biotech latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Krystal Biotech is a good buy for the upcoming year.
Krystal |
About Krystal Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Krystal balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Krystal's non-liquid assets can be easily converted into cash.
Krystal Biotech Cash Flow Chart
Add Fundamental
Net Borrowings
The difference between the amount of new debt a company has taken on and the amount of debt it has paid off during a given period.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Capital Expenditures
Capital Expenditures are funds used by Krystal Biotech to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Krystal Biotech operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Krystal Biotech's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Krystal Biotech current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Krystal Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For more information on how to buy Krystal Stock please use our How to Invest in Krystal Biotech guide.At this time, Krystal Biotech's Change To Netincome is comparatively stable compared to the past year. Begin Period Cash Flow is likely to gain to about 175.1 M in 2024, despite the fact that Change In Working Capital is likely to grow to (36 M).
| 2023 | 2024 (projected) | Stock Based Compensation | 39.9M | 41.9M | Net Borrowings | 2.6M | 2.3M |
Krystal Biotech cash flow statement Correlations
Click cells to compare fundamentals
Krystal Biotech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Krystal Biotech cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Sale Purchase Of Stock | 73.8M | 107.5M | 118.0M | 355.6M | 409.0M | 429.4M | |
| Investments | 1.4M | 3.7M | (158.4M) | (114.1M) | 82.6M | 86.8M | |
| Change In Cash | 83.8M | 80.8M | 73.0M | (179.3M) | 196.4M | 206.2M | |
| Stock Based Compensation | 1.2M | 3.3M | 15.3M | 33.2M | 39.9M | 41.9M | |
| Free Cash Flow | (25.1M) | (40.9M) | (116.3M) | (153.5M) | (100.6M) | (95.6M) | |
| Change In Working Capital | (1.7M) | 928K | 2.1M | 2.8M | (37.9M) | (36.0M) | |
| Total Cashflows From Investing Activities | (5.0M) | (11.2M) | (226.8M) | (114.1M) | (102.7M) | (97.5M) | |
| Other Cashflows From Financing Activities | (5.0M) | (11.2M) | (8.0M) | (649K) | (749K) | (786.5K) | |
| Depreciation | 748K | 1.9M | 2.8M | 4.1M | 5.0M | 5.3M | |
| Other Non Cash Items | 67K | 33K | 1.5M | (690K) | (106.8M) | (101.5M) | |
| Capital Expenditures | 6.4M | 14.8M | 68.3M | 53.0M | 11.8M | 21.6M | |
| Total Cash From Operating Activities | (18.7M) | (26.1M) | (47.9M) | (100.6M) | (88.8M) | (84.4M) | |
| Change To Operating Activities | (1.7M) | 145K | 1.3M | 4.1M | 4.7M | 4.9M | |
| Net Income | (19.1M) | (32.2M) | (69.6M) | (140.0M) | 10.9M | 11.5M | |
| Total Cash From Financing Activities | 107.5M | 118.0M | 347.7M | 35.3M | 202.8M | 129.3M | |
| End Period Cash Flow | 187.5M | 268.3M | 341.2M | 161.9M | 358.3M | 202.5M | |
| Change To Netincome | 1.3M | 4.0M | 16.8M | 32.5M | 37.4M | 39.3M | |
| Change To Liabilities | (1.0M) | 3.1M | 712K | (1.3M) | (1.4M) | (1.4M) | |
| Begin Period Cash Flow | 103.7M | 187.5M | 268.3M | 341.2M | 161.9M | 175.1M | |
| Issuance Of Capital Stock | 107.5M | 118.0M | 355.6M | 36.0M | 203.5M | 164.0M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Krystal Stock Analysis
When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.